Application of scallop glycosaminoglycan in preparing dementia resistant medicine
A scallop glycosaminoglycan and dementia technology, applied in the field of medicine, can solve the problems of strong side effects of anti-dementia drugs, patient death, slow onset of senile dementia, etc., and achieve the effect of improving memory and learning ability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0012] Embodiment 1: Preparation of anti-dementia preparation
[0013] Use distilled water to make a scallop glycosaminoglycan solution with a mass percentage of 5%, add activated carbon with a mass percentage of 1%, stir, heat at 80°C, centrifuge, collect the supernatant, and discard the precipitate; Carry out suction filtration, further remove active carbon and its adsorbed protein and pigment, obtain clear night. The supernatant is successively ultrafiltered with 100k and 5k filter membranes to obtain purified scallop glycosaminoglycans with a molecular weight of 5-100k. The purified scallop glycosaminoglycan is ground into powder and passed through an 80-mesh sieve, and mixed with medicinal starch in a weight ratio of 1:1-10 to prepare capsules with a specification of 50 or 100 mg. Or grind the purified scallop glycosaminoglycan into powder and pass through an 80-mesh sieve, and make 50 or 100 mg tablets according to the wet granulation process.
[0014] Tablet preparati...
experiment example 1
[0020] Experimental Example 1: Scallop Glycosaminoglycan Improves Learning and Memory Abilities in Scopolamine-Induced Dementia Mice
[0021] 1 Materials and reagents
[0022] 1.1 Drugs The scallop glycosaminoglycan was provided by the Department of Pharmacology, Qingdao University School of Medicine.
[0023] 1.2 Animals Kunming (KM) mice: half male and half male, 6 weeks old, 18-22 g, provided by the Experimental Animal Center of Qingdao Institute of Drug Control, Shandong Province.
[0024] 2 Experimental methods
[0025] 2.1 The effect of gavage of scallop glycosaminoglycan on the learning ability of demented mice: 60 mice, half male and half male, were randomly divided into 6 groups, with 10 mice in each group: normal control group (normal saline 10ml kg -1 ), model group (normal saline 10ml·kg -1 ), Piracetam group (Piracetam 300mg·kg -1 ), scallop glycosaminoglycan low, medium and high dose groups (scallop glycosaminoglycan 15, 30, 60 mg·kg -1 ), administered by in...
experiment example 2
[0040] Experimental example 2: Acute toxicity test of scallop glycosaminoglycan
[0041] 1 Materials and reagents
[0042] 1.1 Drugs The scallop glycosaminoglycan was provided by the Department of Pharmacology, Qingdao University School of Medicine, and the scallop glycosaminoglycan was formulated into an aqueous solution with normal saline for use.
[0043] 1.2 Animals KM mice (grade 2), weighing 18-22 g, were provided by Qingdao Experimental Animal Center, certificate number: SCXK (Lu) 20030010.
[0044] 2 Experimental methods
[0045] 2. Fifty 1KM mice, half male and half male, were randomly divided into 5 groups, 10 mice in each group; fasted for 12 hours before the experiment, free to drink water, and controlled room temperature at 20±2°C. One-time intragastric administration of scallop glycosaminoglycan, the doses were 3.20, 2.37, 1.78, 1.33, 0.75 g·kg -1 , The inter-group ratio k=0.75, and the intragastric volume was 0.6ml / only. The general performance of the animal...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More